Guide · Updated November 2026

GLP-1 and Kidney Health: What Nephrologists Are Saying

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are now part of the kidney conversation. In the FLOW trial (NEJM, 2024), semaglutide 1 mg lowered the risk of major kidney disease events by 24% in people with type 2 diabetes and chronic kidney disease. Based on FLOW, Ozempic is now FDA-approved to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and CKD.

Why GLP-1 Kidney Health Is Getting So Much Attention

Most people start a GLP-1 for weight loss or blood sugar control. The kidney conversation is newer, and it is changing how nephrologists think about these drugs.

GLP-1 receptor agonists work by mimicking the incretin hormone GLP-1, which signals satiety and regulates insulin. Researchers think the kidney effects come from a mix of lower blood sugar, lower blood pressure, weight loss, less inflammation, and possibly direct effects in the kidney. Less protein leaking into urine (albuminuria) is one of the markers they watch.

That marker matters. Albuminuria is one of the strongest predictors of kidney disease progression.

I have been on Mounjaro for months tracking my body composition with DEXA scans, and kidney health was not on my radar initially. But after reading the FLOW trial results and talking to my prescriber, I started watching my labs more closely. My eGFR has stayed stable through 22.5% body weight loss, which is reassuring given that rapid weight loss can sometimes temporarily stress the kidneys.

The FLOW Trial: The Landmark Kidney Study

The FLOW trial is the study that changed the conversation. It was the first large randomized trial designed to test whether a GLP-1 receptor agonist could protect the kidneys. Here is what the published results show.

Trial details:

• 3,533 patients with type 2 diabetes and chronic kidney disease (eGFR 50-75 with a urine albumin-to-creatinine ratio over 300, or eGFR 25 to under 50 with a ratio over 100)
• Semaglutide 1.0 mg weekly vs placebo
• Stopped early after a prespecified interim analysis, with a median follow-up of 3.4 years

Key results:

• 24% lower risk of the primary outcome: kidney failure, a 50% or greater drop in eGFR, or death from kidney or cardiovascular causes
• 21% lower risk for the kidney-specific parts of that outcome (hazard ratio 0.79)
• 29% lower risk of cardiovascular death (hazard ratio 0.71)
• eGFR declined more slowly: the yearly slope was 1.16 mL/min/1.73m2 less steep with semaglutide
• 18% lower risk of major cardiovascular events and 20% lower risk of death from any cause

The FDA later added a kidney indication to the Ozempic label based on this trial, in January 2025.

How GLP-1s May Protect the Kidneys

The kidney benefits likely come from several overlapping effects. No single one explains all of it, and researchers are still sorting out how much each contributes.

Blood Sugar and Blood Pressure

GLP-1 medications lower blood sugar and tend to lower blood pressure. Both matter for kidneys already strained by diabetes or hypertension.

Weight Loss and Metabolic Improvement

Obesity contributes to kidney disease through hypertension, insulin resistance, and other routes. In SURMOUNT-1, mean weight change at 72 weeks was -20.9% on tirzepatide 15 mg, and the trial reported improvements in all prespecified cardiometabolic measures. In STEP 1, mean weight change at 68 weeks was -14.9% on semaglutide 2.4 mg.

Possible Direct Effects

Lab and animal studies suggest GLP-1 drugs may reduce inflammation and scarring signals in kidney tissue. How much of this applies to people is still being studied. The open question for nephrologists is how much of the benefit comes from weight and glucose changes versus direct effects on the kidney.

GLP-1 Kidney Benefits vs Other Kidney Drugs

Nephrologists now have three drug classes with positive kidney outcome trials in people with diabetes. The trials used different patients and different outcome definitions, so the percentages are not a head-to-head ranking.

Many people with diabetes and CKD end up on more than one of these drug classes. Which to add, and in what order, is a decision for your nephrologist.

For patients without diabetes, the picture is less clear. FLOW only enrolled people with type 2 diabetes.

What This Means for Different Patients

Here is a plain reading of the evidence. Your nephrologist will weigh your own labs and other medications.

CKD with type 2 diabetes: This is the group FLOW studied, and Ozempic now carries an FDA indication for it.

CKD without diabetes: No large GLP-1 kidney outcome trial has reported in this group yet, as far as we found.

Dialysis or kidney transplant: Data are limited. If you take a drug with a narrow therapeutic range, the tirzepatide labels advise monitoring because these drugs delay gastric emptying and can change how oral medications are absorbed. Ask your transplant or kidney team before starting.

GLP-1 Kidney Considerations for Weight Loss Patients

If you are taking a GLP-1 primarily for weight loss and do not have diagnosed kidney disease, there are still a few things worth knowing.

Dehydration is the main kidney risk on the label. The Zepbound prescribing information warns of acute kidney injury, in some cases requiring dialysis, mostly in people who became dehydrated from nausea, vomiting, or diarrhea. It tells prescribers to monitor kidney function in patients with those side effects.

Watch your creatinine. Creatinine comes from muscle, so changes in muscle mass during weight loss can shift it. A small creatinine change does not necessarily mean kidney damage. Ask your doctor whether a cystatin C test makes sense, since it is less affected by muscle mass.

Stay hydrated. GLP-1 side effects like nausea and vomiting can lead to dehydration. This is most common in the early weeks of treatment or during dose increases. If you cannot keep fluids down, call your prescriber.

Get baseline labs. Before starting any GLP-1, ask for a basic metabolic panel that includes creatinine and eGFR. If your eGFR is below 60, mention it to your prescriber. The GLP-1 side effects guide covers what labs to request and when.

Ask about NSAIDs. If you take ibuprofen or naproxen regularly for joint pain, that combined with low fluid intake can be hard on kidneys. Talk to your doctor about alternatives.

GLP-1 Kidney Data by Drug

Not all GLP-1s have the same level of kidney evidence. Here is where each major drug stands.

Tirzepatide is the one to watch. In SURMOUNT-5 (NEJM, 2025), it produced a mean weight change of -20.2% versus -13.7% for semaglutide. Whether that translates into stronger kidney protection has not been shown in a kidney outcome trial yet.

Should You Get Your Kidneys Checked on a GLP-1?

Yes. Even if you are taking a GLP-1 purely for weight loss.

Here is the lab schedule I follow with my prescriber. Yours may differ.

• Before starting: Baseline metabolic panel (creatinine, eGFR, BUN) plus urine albumin-to-creatinine ratio (UACR)
• At 3 months: Repeat creatinine and eGFR. Check UACR if baseline was elevated.
• Every 6 months ongoing: Metabolic panel. Add UACR annually.

If you are already tracking body composition with DEXA scans, adding a kidney panel to your lab rotation is simple. Some online GLP-1 providers include basic labs, but not all check UACR. Ask specifically.

For anyone with known CKD, type 2 diabetes, or hypertension, your nephrologist will likely want more frequent monitoring.

FAQ

Can GLP-1 medications damage your kidneys?

The main kidney risk on the labels is acute kidney injury from dehydration, usually after severe nausea, vomiting, or diarrhea. In people with type 2 diabetes and CKD, the FLOW trial showed semaglutide lowered the risk of major kidney disease events by 24%. Stay hydrated, especially during dose increases, and call your prescriber if you cannot keep fluids down.

Do nephrologists recommend GLP-1s for kidney disease?

For CKD with type 2 diabetes, the evidence is now strong. FLOW was positive, and the FDA added a kidney indication to Ozempic based on it. For patients without diabetes, the evidence is still accumulating.

Which GLP-1 is best for kidney protection?

Semaglutide (Ozempic) at 1.0 mg has the strongest evidence, from the FLOW trial. Liraglutide and dulaglutide showed kidney benefits in secondary analyses of heart trials. Tirzepatide does not yet have a completed kidney outcome trial.

Does weight loss from GLP-1s help or hurt kidneys?

Weight loss improves blood pressure, blood sugar, and other risk factors that drive kidney disease. The risk to watch is dehydration from GI side effects, which can cause acute kidney injury. Get baseline labs and repeat them during treatment.

Should I take a GLP-1 if I have stage 3 CKD?

Talk to your nephrologist. FLOW enrolled people with type 2 diabetes and an eGFR as low as 25 and showed benefit. The Ozempic label does not recommend a dose adjustment for kidney impairment, but your prescriber should monitor you closely, especially if you have GI side effects. Check our cost guide and insurance coverage guide for coverage options.

What we checked

This AI-assisted public-source desk check reviewed the FLOW, SURMOUNT-1, STEP 1, SURMOUNT-5, CREDENCE, DAPA-CKD, FIDELIO-DKD, LEADER, and REWIND trial abstracts on PubMed, plus the current Ozempic and Zepbound prescribing information, on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.

Related

Guides:

• Side Effects Guide · Gallbladder Problems · GLP-1 and Anxiety
• Muscle Preservation Protocol · Body Composition Guide · DEXA Scan Results
• How GLP-1s Work · Fat Loss vs Weight Loss · Side Effects Month by Month

Provider Reviews: Ro · Hims · MEDVi · Found · Calibrate

Compare: All Providers · Best GLP-1 Programs · All Guides